Boostrix: Clinical Trials

18 trials of Boostrix, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

16 completed, 1 active not recruiting, 1 withdrawn. 18 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	18	Completed 16, Active not recruiting 1, Withdrawn 1
Phase 2	1	Withdrawn 1

Follow Boostrix: new trials by email Literature Review of Boostrix trials Research Report on Boostrix

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women dTpa - Diphtheria-Tetanus-acellular Pertussis Vaccines	Phase 3	Active not recruiting	GlaxoSmithKline	102	2026-06-29	2026-09-08
GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age GBS-NN/NN2 vaccine, Tdap vaccine, Placebo - Streptococcus Agalactiae Infection	Phase 2 / Phase 3	Withdrawn	Minervax ApS		2024-12-17	2026-10-13
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age RSV MAT vaccine, dTpa vaccine - Respiratory Syncytial Virus Infections	Phase 3	Completed	GlaxoSmithKline	9	2022-02-02	2023-04-07
Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects Boostrix - Diphtheria-Tetanus-acellular Pertussis Vaccines	Phase 3	Completed	GlaxoSmithKline	448	2018-01-26	2020-10-27
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Non-Influenza Comparator (Boostrix) - Influenza	Phase 3	Completed	Seqirus	6790	2016-09-30	2020-06-17
Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children Boostrix™ - Diphtheria, Tetanus	Phase 3	Completed	GlaxoSmithKline	302	2014-02-22	2018-08-02
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older Herpes Zoster vaccine GSK 1437173A, Boostrix - Herpes Zoster	Phase 3	Completed	GlaxoSmithKline	935	2014-02-07	2018-04-24
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults Boostrix - Tetanus, Acellular Pertussis	Phase 3	Completed	GlaxoSmithKline	165	2013-01-31	2018-06-06
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults Meningococcal vaccine GSK134612, Cervarix®, Boostrix® - Infections, Meningococcal	Phase 3	Completed	GlaxoSmithKline	1300	2013-01-11	2018-07-03
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age Meningococcal vaccine GSK134612, Boostrix® - Infections, Meningococcal	Phase 3	Completed	GlaxoSmithKline	692	2013-01-10	2017-09-06
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine. Boostrix®, Decavac™ - Tetanus, Acellular Pertussis	Phase 3	Completed	GlaxoSmithKline	1332	2009-02-17	2020-01-03
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 Taking of blood samples, Boostrix, Adacel - Acellular Pertussis, Tetanus	Phase 3	Completed	GlaxoSmithKline	1954	2007-06-01	2020-05-01
Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine Boostrix, Chinese DT vaccine - Diphtheria, Acellular Pertussis	Phase 3	Completed	GlaxoSmithKline	660	2007-03-01	2016-10-28
Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. Boostrix - Tetanus, Diphtheria	Phase 3	Completed	GlaxoSmithKline	30	2007-01-01	2016-10-27
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults Fluarix®, Boostrix® - Acellular Pertussis, Diphtheria	Phase 3	Completed	GlaxoSmithKline	1726	2006-10-23	2019-06-10
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years Boostrix™, ADACEL® - Acellular Pertussis, Diphtheria	Phase 3	Completed	GlaxoSmithKline	2337	2006-07-13	2018-08-07
PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers 23vPPV, dTpa (Pneumovax, Boostrix) - Middle Ear Effusion, Tympanic Membrane Perforation	Phase 3	Completed	Menzies School of Health Research	227	2006-06-01	2014-07-10
Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine, Boostrix™, GSK Biologicals' IPV vaccine - Tetanus, Diphtheria	Phase 3	Completed	GlaxoSmithKline	806	2002-01-01	2016-09-07

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding